Factors that impact choice of antidepressant treatment in medically complex patients.
In medically complex patients with multiple comorbid illnesses who require concomitant medications, selecting the optimal antidepressant (ie, low risk of adverse effects and/or pharmacokinetic interactions) for an individual patient is critical for positive long-term patient outcomes. The serotonin-norepinephrine reuptake inhibitors (SNRls) are increasingly being used as first-line treatment for major depressive disorder (MDD) and may prove beneficial for treatment of medically complex patients.Thus, it is key for clinicians to evaluate the differences in the pharmacokinetic and tolerability profiles of the SNRI class of antidepressants, evaluating differences both within the class and compared with other antidepressants used to treat MDD.
Dago
Pedro Luis
PL
Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine of Northwestern University, 446 East Ontario Avenue, Chicago, IL 60611-3008, USA. PDago@nmff.org
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002755:Choice Behavior / Q000502:physiology; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008107:Liver Diseases / Q000209:etiology; D008297:Male; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors